Physician profile
Theodore Eckman
NPI 1255691820
$2,822.74
in general payments reported to CMS, 2019-2025
29 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $118 · 2021: $347 · 2022: $384 · 2023: $449 · 2024: $519 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,092.72 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $267.14 | 2022-2025 | General - Pain Management |
| Medtronic, INC. | $237.41 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Astrazeneca Pharmaceuticals Lp | $163.87 | 2023-2025 | Tezspire, Breztri, Fasenra |
| Si-Bone, INC. | $139.85 | 2019-2025 | |
| Vertos Medical, INC. | $105.51 | 2023-2024 | Mild Device Kit |
| Nevro Corp. | $90.23 | 2020-2023 | Senza |
| Lilly USA, LLC | $84.04 | 2023-2025 | Amyvid, Zepbound |
| Mylan Specialty L.P. | $65.72 | 2022-2023 | Yupelri |
| Biodelivery Sciences International, INC. | $55.64 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $52.02 | 2023-2025 | Exparel, Iovera, Zilretta |
| Averitas Pharma INC. | $49.14 | 2023-2024 | Qutenza |
| Stryker Corporation | $41.90 | 2024-2025 | Mild Device Kit, Avaflex |
| Genentech USA, INC. | $40.64 | 2025 | Xolair |
| Relievant Medsystems, INC. | $38.63 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.06 | 2023-2024 | Tezspire, Aimovig |
| Saluda Medical Americas, INC. | $29.95 | 2025 | Evoke |
| Grt US Holding, INC. | $26.71 | 2022 | |
| Stimwave Technologies Incorporated | $24.52 | 2021 | |
| Genzyme Corporation | $22.16 | 2025 | |
| Glaxosmithkline, LLC. | $21.46 | 2024 | Trelegy Ellipta, Arexvy |
| Alexion Pharmaceuticals, INC. | $21.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2023 | Nuedexta |
| Daiichi Sankyo INC. | $20.39 | 2019 | |
| Pacira Therapeutics, INC. | $19.55 | 2019 | |
| Harmony Biosciences LLC | $17.24 | 2023 | Wakix |
| Avanir Pharmaceuticals, INC. | $15.08 | 2022 | |
| Medtronic USA, INC. | $13.43 | 2020 | |
| Hikma Pharmaceuticals USA | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.